Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 2,710

The DOI matches its Crossref record; 214 of the 214 references it cites were found in a registry or an index.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

Open access
Smolen, Josef S, Landewé, Robert B M, Bijlsma, Johannes W J, Burmester, Gerd R, Dougados, Maxime, Kerschbaumer, Andreas, McInnes, Iain B, Sepriano, Alexandre, van Vollenhoven, Ronald F, de Wit, Maarten, Aletaha, Daniel, Aringer, Martin, Askling, John, Balsa, Alejandro, Boers, Maarten, den Broeder, Alfons A, Buch, Maya H, Buttgereit, Frank, Caporali, Roberto, Cardiel, Mario Humberto, De Cock, Diederik, Codreanu, Catalin, Cutolo, Maurizio, Edwards, Christopher John, van Eijk-Hustings, Yvonne, Emery, Paul, Finckh, Axel, Gossec, Laure, Gottenberg, Jacques-Eric, Hetland, Merete Lund, Huizinga, Tom W J, Koloumas, Marios, Li, Zhanguo, Mariette, Xavier, Müller-Ladner, Ulf, Mysler, Eduardo F, da Silva, Jose A P, Poór, Gyula, Pope, Janet E, Rubbert-Roth, Andrea, Ruyssen-Witrand, Adeline, Saag, Kenneth G, Strangfeld, Anja, Takeuchi, Tsutomu, Voshaar, Marieke, Westhovens, René, van der Heijde, Désirée·2020·Annals of the Rheumatic Diseases

Abstract

Objectives To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for the most recent developments in the field. Methods An international task force considered new evidence supporting or contradicting previous recommendations and novel therapies and strategic insights based on two systematic literature searches on efficacy and safety of disease-modifying antirheumatic drugs (DMARDs) since the last update (2016) until 2019. A predefined voting process was applied, current levels of evidence and strengths of recommendation were assigned and participants ultimately voted independently on their level of agreement with each of the items. Results The task force agreed on 5 overarching principles and 12 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GCs); biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, sarilumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib). Guidance on monotherapy, combination therapy, treatment strategies (treat-to-target) and tapering on sustained clinical remission is provided. Cost and sequencing of b/tsDMARDs are addressed. Initially, MTX plus GCs and upon insufficient response to this therapy within 3 to 6 months, stratification according to risk factors is recommended. With poor prognostic factors (presence of autoantibodies, high disease activity, early erosions or failure of two csDMARDs), any bDMARD or JAK inhibitor should be added to the csDMARD. If this fails, any other bDMARD (from another or the same class) or tsDMARD is recommended. On sustained remission, DMARDs may be tapered, but not be stopped. Levels of evidence and levels of agreement were mostly high. Conclusions These updated EULAR recommendations provide consensus on the management of RA with respect to benefit, safety, preferences and cost.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2019-216655

Cites

214 of 214 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 214 references

Cited by

See all 2,710

Metadata

Authors
Smolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van Vollenhoven, R. F., de Wit, M., Aletaha, D., Aringer, M., Askling, J., Balsa, A., Boers, M., den Broeder, A. A., Buch, M. H., Buttgereit, F., Caporali, R., Cardiel, M. H., De Cock, D., Codreanu, C., Cutolo, M., Edwards, C. J., van Eijk-Hustings, Y., Emery, P., Finckh, A., Gossec, L., Gottenberg, J.-E., Hetland, M. L., Huizinga, T. W. J., Koloumas, M., Li, Z., Mariette, X., Müller-Ladner, U., Mysler, E. F., da Silva, J. A. P., Poór, G., Pope, J. E., Rubbert-Roth, A., Ruyssen-Witrand, A., Saag, K. G., Strangfeld, A., Takeuchi, T., Voshaar, M., Westhovens, R., & van der Heijde, D.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2020-06
Volume
79
Issue
6
Pages
685-699
ISSN
0003-4967 (ISSN-L)
OpenAlex
W4231972505
Cited by
2,710
References
214
FWCI
320.67
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. https://app.cochat.ai/papers/10.1136/annrheumdis-2019-216655
The paper
Smolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van Vollenhoven, R. F., de Wit, M., Aletaha, D., Aringer, M., Askling, J., Balsa, A., Boers, M., den Broeder, A. A., Buch, M. H., Buttgereit, F., Caporali, R., . . . van der Heijde, D. (2020). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2019-216655

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.